Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Interferon gamma-1b: Phase III started

    Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland Product: Interferon gamma-1b (Actimmune) Business: Neurology Molecular target: Interferon (IFN) gamma receptor Description: Interferon (IFN) gamma-1b Indication: Treat …

    Published on 6/22/2015
  • ITI-007: Completed Phase III enrollment

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.Y. Product: ITI-007 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Dopamine receptor Description: Dual serotonin (5-HT2A) receptor antagonist …

    Published on 6/22/2015
  • MGN1703: Phase I/IIa started

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Infectious Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (…

    Published on 6/22/2015
  • ND0612H: Phase I started

    NeuroDerm Ltd. (NASDAQ:NDRM), Ness Ziona, Israel Product: ND0612H Business: Neurology Molecular target: NA Description: High-dose formulation of liquid levodopa and carbidopa delivered via a continuous, subcutaneous …

    Published on 6/22/2015
  • Remimazolam: Phase III started

    Paion AG (Xetra:PA8), Aachen, Germany Product: Remimazolam (CNS 7056, ONO-2745) Business: Neurology Molecular target: GABA A receptor Description: Ultra-short-acting GABA A receptor modulator Indication: Procedural …

    Published on 6/22/2015
  • Resunab: Phase II started

    Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Product: Resunab (JBT-101) Business: Autoimmune Molecular target: Cannabinoid CB2 receptor (CNR2) Description: Synthetic cannabinoid CB2 receptor (CNR2)…

    Published on 6/22/2015
  • RhNAGLU: Completed Phase I/II enrollment

    Synageva BioPharma Corp. (NASDAQ:GEVA), Lexington, Mass. Product: RhNAGLU (SBC-103) Business: Endocrine/Metabolic Molecular target: N-acetylglucosaminidase alpha (NAGLU) Description: Recombinant human N-…

    Published on 6/22/2015
  • Rhopressa: Phase III amended

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 6/22/2015
  • RPL554: Phase IIa started

    Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc (LSE:VRP), London, U.K. Product: RPL554 Business: Inflammation Molecular target: Phosphodiesterase-3 (PDE-3); Phosphodiesterase-4 (PDE-4) Description: Nebulized …

    Published on 6/22/2015
  • Setmelanotide: Phase II started

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Rhythm Pharmaceuticals Inc., Boston, Mass. Product: Setmelanotide (RM-493) (formerly BIM 22493) Business: Endocrine/Metabolic Molecular target: …

    Published on 6/22/2015
  • Setmelanotide: Phase II started

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Rhythm Pharmaceuticals Inc., Boston, Mass. Product: Setmelanotide (RM-493) (formerly BIM 22493) Business: Endocrine/Metabolic Molecular target: …

    Published on 6/22/2015
  • SYN-004: Phase IIa started

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-004 (formerly P3A) Business: Infectious Molecular target: NA Description: Second-generation, oral beta lactamase (LACTB) that binds with and neutralizes…

    Published on 6/22/2015
  • VAX2012Q: Phase II started

    VaxInnate Corp., Cranbury, N.J. Product: VAX2012Q Business: Infectious Molecular target: NA Description: Recombinant quadrivalent hemagglutinin seasonal influenza vaccine Indication: Prevent seasonal influenza infection…

    Published on 6/22/2015
  • VR942: Phase I started

    UCB Group (Euronext:UCB), Brussels, Belgium Vectura Group plc (LSE:VEC), Chippenham, U.K. Product: VR942 Business: Inflammation Molecular target: NA Description: Dry powder immunomodulatory biologic Indication: Treat …

    Published on 6/22/2015
  • 514G3: Phase I/II started

    XBiotech Inc. (NASDAQ:XBIT), Austin, Texas Product: 514G3 Business: Infectious Molecular target: NA Description: mAb against Staphylococcus aureus based on True Human technology Indication: Treat Staphylococcus aureus …

    Published on 6/15/2015
  • Brilacidin-OM: Phase II started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin-OM Business: Other Molecular target: NA Description: Oral rinse formulation of a synthetic defensin mimetic Indication: Treat and prevent oral mucositis…

    Published on 6/15/2015
  • Brincidofovir: Completed Phase III enrollment

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Product: Brincidofovir (CMX001) Business: Infectious Molecular target: NA Description: Oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations …

    Published on 6/15/2015
  • Cenicriviroc: Completed Phase IIb enrollment

    Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Cenicriviroc (formerly TBR-652) Business: Hepatic Molecular target: CC chemokine receptor …

    Published on 6/15/2015
  • CPX-351: Completed Phase II enrollment

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 6/15/2015
  • GI-6301: Phase II started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. GlobeImmune Inc. (NASDAQ:GBIM), Louisville, Colo. Product: GI-6301 Business: Cancer Molecular target: NA Description: Whole heat-killed recombinant Saccharomyces cerevisiae …

    Published on 6/15/2015
  • Luminate: Phase II started

    Allegro Ophthalmics LLC, San Juan Capistrano, Calif. Product: Luminate (ALG-1001) Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF) Description: Anti-integrin oligopeptide Indication: …

    Published on 6/15/2015
  • Metyrapone/oxazepam: Phase I started

    Embera NeuroTherapeutics Inc., Shreveport, La. Product: Metyrapone/oxazepam (EMB-001) Business: Neurology Molecular target: GABA A receptor; Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Description: …

    Published on 6/15/2015
  • PRO 140: Phase III started

    CytoDyn Inc. (OTCBB:CYDY), Vancouver, Wash. Product: PRO 140 Business: Infectious Molecular target: CC chemokine receptor 5 (CCR5) (CD195) Description: Humanized mAb against CC chemokine receptor 5 (CCR5; CD195) …

    Published on 6/15/2015
  • PRS-080: Phase I ongoing

    Pieris Pharmaceuticals Inc. (Pink:PIRS), Freising-Weihenstephan, Germany Product: PRS-080 Business: Hematology Molecular target: Hepcidin Description: Anticalin targeting hepcidin Indication: Treat anemia Endpoint: …

    Published on 6/15/2015
  • PRX003: Phase I started

    Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland Product: PRX003 Business: Autoimmune Molecular target: Melanoma cell adhesion molecule (MCAM) (MUC18) (CD146) Description: mAb targeting melanoma cell adhesion molecule…

    Published on 6/15/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993